150+ Indian healthcare brands manage their Google Business Profile with Angryturtle.
The AI-native GBP intelligence platform built for Indian healthcare — Rank OS scoring across 5 dimensions, AI-answer visibility via Ask Maps, geo-grid rank tracking, NMC-compliant review reply, and direct write-back to Google. All in one loop.
Prefer done-for-you? ICG's healthcare-specialist team runs Angryturtle for you at ₹25,000/- per month and up. Book a local SEO diagnostic with ICG →
A pharma marketing agency in India operates inside a fundamentally different regulatory perimeter from a healthcare marketing agency. Pharma marketing covers pharmaceutical companies, medical device manufacturers, diagnostics companies, and biotech firms — buyers whose marketing is regulated by the Drugs and Cosmetics Act 1940, Schedule H restrictions on prescription-only advertising, DPCO (Drug Price Control Order), OPPI Code of Marketing Practice, and increasingly the DPDP Act 2023 for HCP (Healthcare Professional) engagement data. ICG runs pharma marketing for pharmaceutical and medical device buyers alongside our core healthcare-provider practice, using compliance frameworks calibrated for pharma-specific regulation rather than the NMC frameworks that apply to clinics and hospitals.
Why pharma marketing is a different discipline from healthcare marketing
The buyer is different. A hospital or clinic markets to patients (or to families of patients). A pharma company markets to healthcare professionals (HCPs) — the doctors who prescribe the pharma company's products. Occasionally pharma companies do direct-to-consumer marketing for over-the-counter (OTC) products or disease-awareness campaigns, but the majority of pharma marketing is HCP-focused.
The regulatory perimeter is different. Hospitals and clinics operate inside NMC Ethics Code 2026 restrictions on medical practitioner conduct. Pharma companies operate inside Drugs and Cosmetics Act restrictions on drug advertising, Schedule H restrictions on prescription-drug promotion to consumers (prescription drugs cannot be advertised to the general public), DPCO price controls (advertised prices cannot exceed DPCO ceilings), and OPPI (Organisation of Pharmaceutical Producers of India) Code of Marketing Practice restrictions on HCP engagement.
The channels are different. Hospitals use Google Ads, Meta ads, Google Business Profile, WhatsApp lifecycle. Pharma companies use medical journals, HCP conferences and CME (Continuing Medical Education) events, medical rep visits, HCP-facing digital platforms (Medscape India, DoctorsHangout, PulseMD), and increasingly HCP-targeted content on LinkedIn.
The metric is different. Hospitals measure cost-per-qualified-lead and cost-per-booked-consultation. Pharma companies measure prescription volume (Rx count), HCP engagement quality (attended events, downloaded materials, requested samples), and eventual market share for the promoted product.
The three buyer profiles inside pharma marketing
1. Pharmaceutical companies (branded and generic)
Pharma companies market prescription drugs to HCPs. Products range from cardiac drugs (ACE inhibitors, beta blockers, statins), diabetes drugs (insulins, oral hypoglycemics, GLP-1 agonists), oncology drugs (biologics, immunotherapies), psychiatric drugs (antidepressants, antipsychotics), women's health drugs (contraceptives, fertility drugs, HRT), and hundreds of other categories.
Marketing scope for a pharma company typically includes: HCP-facing content development (clinical protocols, drug information summaries, mechanism-of-action explainers), medical conference sponsorship and content management, CME event organisation and content, medical rep enablement (visual aids, tablet-based detailing tools, sample tracking), HCP engagement platforms (webinars, symposia, educational grants), and market research on prescriber behaviour and preferences.
Regulatory compliance: Drugs and Cosmetics Act restrictions on drug advertising claims (advertised benefits must match the approved label), Schedule H prohibition on consumer advertising of prescription drugs, DPCO price ceiling compliance, OPPI code compliance on HCP engagement (gift limits, sample distribution, engagement documentation), and DPDP Act 2023 compliance on HCP contact data handling.
2. Medical device manufacturers
Medical device companies market surgical implants, diagnostic equipment, patient monitoring systems, catheters, prosthetics, and other medical devices to hospitals, doctors, and healthcare institutions. Products include cardiac stents, joint replacement implants, imaging equipment, ventilators, ECG machines, and specialty devices for various clinical uses.
Marketing scope for medical devices: hospital-facing sales content (product specifications, clinical evidence summaries, cost-benefit analyses), surgeon education (procedure training, case-based learning), conference presence at surgical society meetings, KOL (Key Opinion Leader) engagement with prominent specialists, hospital-network account management, and installation and training services.
Regulatory compliance: Medical Device Rules 2017 (registration and post-market surveillance), CDSCO (Central Drugs Standard Control Organisation) approval requirements, ISO and BIS certification standards, hospital procurement compliance (empanelled vendor status, government procurement rules), and DPDP Act 2023 for HCP data handling.
3. Diagnostics and biotech companies
Diagnostics companies market lab tests, imaging services, molecular diagnostics, and point-of-care testing to hospitals, clinics, and increasingly directly to patients. Biotech companies market specialised biological products (biosimilars, gene therapies, personalised medicine) to specialist HCPs.
Marketing scope varies: for lab-network diagnostics, per-location local SEO overlaps meaningfully with healthcare-provider marketing (labs have GBP profiles, patient reviews, and local ranking dynamics similar to clinics). For B2B diagnostics selling to hospitals, HCP-facing content and hospital-account management dominate.
Regulatory compliance: for labs, NABL (National Accreditation Board for Testing and Calibration Laboratories) accreditation, ICMR guidelines for specific test categories, PC-PNDT for prenatal diagnostics. For biotech, CDSCO approvals plus specific product-category regulations.
What pharma marketing scope looks like at ICG
ICG's pharma marketing service covers the pharma-buyer-specific channels and compliance frameworks. The scope includes:
HCP-facing digital content. Clinical protocol summaries, drug information monographs, mechanism-of-action explainers, patient-outcome case studies (anonymised, published-with-consent), medical journal article summaries, treatment guideline references. Every content asset passes through medical-affairs review before publishing to ensure claims match approved product labels and clinical evidence.
Medical conference and CME event support. Content development for conference sessions, sponsored symposia, and CME programmes. Post-event content distribution to HCP audiences. Documentation of engagement events per OPPI code requirements.
Medical rep enablement. Tablet-based visual aids for detailing, clinical evidence summaries formatted for rep use, sample distribution tracking systems integration, and rep-content refresh cycles as new clinical data emerges.
HCP engagement platform management. Content on medical-education platforms (Medscape India, DoctorsHangout, PulseMD), LinkedIn HCP-targeted content, and pharma company's own HCP portal if operated.
Market research and analytics. Prescriber behaviour analysis, market share tracking, competitive intelligence on rival pharma products, and post-launch performance measurement.
Compliance review as a first-class workflow. Every content asset — HCP-facing, patient-facing (OTC only), digital, print, conference — passes through Drugs and Cosmetics Act / Schedule H / DPCO / OPPI compliance review before publishing.
What ICG's pharma marketing doesn't do
Consumer advertising of prescription drugs. Schedule H prohibits it; no legitimate pharma marketing agency does it.
Payments to HCPs beyond OPPI-compliant limits. Gift and engagement limits under OPPI are strict; ICG's pharma engagement stays inside those limits.
Marketing to patients for prescription-only products. Only OTC and disease-awareness campaigns can target consumers directly, and even those operate inside specific claim restrictions.
Cross-promotion with unrelated pharma products. ICG doesn't run cross-promotion campaigns that could constitute conflicts of interest between competing pharma buyers.
Off-label promotion. Every claim tied to approved product label; off-label indications aren't promoted regardless of clinical support.
How pharma marketing differs from ICG's healthcare-provider marketing
The most obvious difference: ICG's healthcare-provider marketing (clinics, hospitals) is customer-facing (patients are the customer). ICG's pharma marketing is B2B and B2H (business and healthcare-professional facing). Different buyer, different message, different channel, different metric.
The most subtle difference: healthcare-provider marketing operates inside NMC Ethics Code 2026 (medical practitioner conduct restrictions). Pharma marketing operates inside Drugs and Cosmetics Act / Schedule H / DPCO / OPPI. Some compliance concepts overlap (both restrict outcome claims), most do not. A generalist agency running both without frameworks specific to each will make compliance mistakes in whichever framework it understands less.
ICG's team includes members with pharma-specific experience (from pharma companies) as well as healthcare-provider experience (from clinics and hospitals). Pharma work stays within the pharma-team's remit; healthcare-provider work stays within the provider-team's remit. The two teams share tools and infrastructure but operate as distinct disciplines.
Where Angryturtle fits for pharma buyers
Angryturtle is ICG's GBP intelligence platform for healthcare providers (clinics, hospitals, doctors). Pharma companies don't typically have consumer-facing GBP profiles that need this kind of local SEO management.
Angryturtle relevance for pharma buyers is limited to two edge cases: (1) pharma companies with consumer-facing product websites or corporate presence in specific cities, where a corporate GBP for headquarters or key manufacturing locations might benefit from professional management, and (2) diagnostics companies operating lab networks where each lab location has its own GBP that behaves like a healthcare-provider profile.
For core pharma marketing (HCP-facing content, conference support, rep enablement, engagement platforms), Angryturtle isn't the right tool. ICG's pharma team uses different infrastructure — content management systems calibrated for medical-affairs workflows, HCP engagement platforms, and traditional CRM systems for HCP account management.
Pricing tiers for pharma marketing
Small pharma company or single-brand launch: ₹1,50,000-₹3,00,000/month covers HCP-facing content development for one product family, medical conference support for 2-4 events per year, and basic HCP engagement platform content. Suits emerging pharma brands or specific brand-launch initiatives.
Mid-size pharma company: ₹3,00,000-₹8,00,000/month covers HCP-facing content for multiple product families, comprehensive medical conference and CME programme, rep enablement content refresh, and HCP engagement platform management. Suits pharma companies with 5-20 marketed brands.
Large pharma company or MNC subsidiary: ₹8,00,000+/month plus custom pricing for portfolio-scale requirements. Suits large pharma operations with 20+ brands, integrated CME programmes, KOL engagement across specialities, and portfolio-wide market intelligence needs.
Media spend for pharma (medical journal advertising, conference sponsorship fees, HCP platform advertising) runs separately.
Related reading
- Healthcare marketing agency India — ICG's core healthcare-provider marketing (distinct from pharma)
- Healthcare local SEO agency India — for the healthcare-provider local SEO scope
- Healthcare marketing companies India — market map of healthcare marketing archetypes
FAQ
What is a pharma marketing agency?
An agency that provides marketing services to pharmaceutical, medical device, diagnostic, and biotech companies. Distinct from healthcare-provider marketing agencies (which serve clinics and hospitals) because the buyers, compliance frameworks, channels, and metrics all differ.
How is pharma marketing different from healthcare marketing?
Buyer is different (HCPs and hospitals vs patients), regulatory perimeter is different (Drugs and Cosmetics Act / Schedule H / DPCO / OPPI vs NMC Ethics Code), channels are different (medical journals, CME events, HCP platforms vs Google Ads / GBP / WhatsApp), and metrics are different (prescription volume vs cost-per-consultation).
Can consumer advertising promote prescription drugs?
No. Schedule H of the Drugs and Cosmetics Act prohibits consumer advertising of prescription-only drugs. Only OTC products and disease-awareness campaigns can target consumers directly, with specific claim restrictions.
What is OPPI Code of Marketing Practice?
The Organisation of Pharmaceutical Producers of India's self-regulatory code covering HCP engagement practices — gift limits, sample distribution rules, engagement documentation requirements, and other conduct standards for pharma-HCP interactions. Adherence is voluntary but represents industry consensus on ethical HCP engagement.
Does ICG's pharma marketing include Google Ads?
Rarely, because Google Ads for prescription drugs runs into Schedule H issues immediately. OTC product advertising via Google is possible with claim restrictions. Corporate brand advertising for pharma companies is possible. HCP-targeted advertising via LinkedIn is more common than Google for pharma.
How much does pharma marketing cost?
₹1,50,000-₹8,00,000+ per month depending on portfolio size and scope. Smaller than hospital marketing budgets in absolute terms only for narrower-scope engagements; large pharma portfolio management runs into crores per year.
Can a healthcare marketing agency also do pharma marketing?
Only if the agency has pharma-specific expertise and infrastructure. Compliance frameworks are meaningfully different. Most healthcare-provider marketing agencies don't do pharma; most pharma marketing agencies don't do healthcare-provider work.
What is Drugs and Cosmetics Act?
The 1940 Act (with subsequent amendments) that regulates pharmaceutical drugs and cosmetic products in India, including advertising and promotional activities. Schedule H is the schedule restricting prescription-drug promotion.
How does ICG handle KOL engagement for pharma buyers?
KOL identification, engagement planning, content collaboration, event coordination, and compliant documentation. All within OPPI code limits on payments and engagement gifts.
Does ICG do medical rep enablement content?
Yes. Tablet-based visual aids, clinical evidence summaries in rep-friendly formats, sample distribution tracking system integration, and content refresh cycles as new clinical data emerges.
What about medical device marketing specifically?
Handled under ICG's pharma marketing service. Medical Device Rules 2017 compliance, hospital-account management, surgeon education and KOL engagement, conference presence at surgical society meetings.
How does ICG price for medical device buyers?
Similar tier structure to pharmaceutical companies — smaller device companies at ₹1,50,000-₹3,00,000/month, mid-size at ₹3,00,000-₹8,00,000/month, large multinational device companies at ₹8,00,000+ with custom scope.
